Search results
Results for “semaglutide”
Check each result's review status before you open it.
Tip: press / to focus. Press Esc to clear.
What do the evidence levels mean?
These labels give a quick guide. Established means strong evidence supports one defined use. Emerging means studies in people exist, but important questions remain. Insufficient means reliable studies in people are missing or too limited.
21 results for “semaglutide”
Exact names come first.Start with the full review for this peptide.
Read the review →Semaglutide
This review covers Ozempic, Rybelsus, Wegovy, and the Wegovy HD strength. Their forms, approved uses, and labels differ.
Tirzepatide
Tirzepatide is the active ingredient in Mounjaro and Zepbound. Each approved product has its own uses and safety information. An approval for one product does not automatically apply to the other.
Cagrilintide
Researchers designed this peptide to act like the body's amylin signal. Human weight-loss studies exist, but no FDA-approved product exists.
“Semaglutide is FDA-approved.”
FDA approves a specific product for specific uses. The current Wegovy label lists different forms, groups of people, uses, and limits.
“Compounded semaglutide is the same as an approved product.”
FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.
“A result in one population proves the same benefit for everyone.”
A study supports only the people, product form, dose, length, approved use, and result that it tested.
“CagriSema is cagrilintide alone.”
CagriSema is the investigational combination of cagrilintide and semaglutide. Evidence from the combination is not evidence for cagrilintide alone.
OZEMPIC (semaglutide) prescribing information, revised 05/2026
U.S. Food and Drug Administration · Drug label · 2026
RYBELSUS (semaglutide) prescribing information, revised 10/2025
U.S. Food and Drug Administration · Drug label · 2025
WEGOVY (semaglutide) prescribing information, revised 06/2026
U.S. Food and Drug Administration · Drug label · 2026
FDA’s concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration · Regulatory · 2026
Drug approvals and databases
U.S. Food and Drug Administration · Regulatory · 2026
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
PubMed · Journal of Medicinal Chemistry · Preclinical · 2015
FDA substance record: semaglutide identity (not an approval record)
U.S. Food and Drug Administration · Reference · 2026
2026 Monitoring Program
World Anti-Doping Agency · Anti-doping · 2026
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
PubMed · New England Journal of Medicine · Randomized trial · 2021
Coadministered cagrilintide and semaglutide in adults with overweight or obesity
PubMed · New England Journal of Medicine · Randomized trial · 2025
Cagrilintide with semaglutide: human exposure and effects
PubMed · The Lancet · Human pharmacology · 2021
Semaglutide vs. tirzepatide: weight loss, risks, and product differences
Compare semaglutide and tirzepatide. See what two direct studies found, how FDA-approved products differ, and which risks and evidence limits matter.
Which peptides are FDA-approved? A product-by-product directory.
A limited directory of FDA-approved peptide medicines. Each entry names the brand, application, dosage form, route, and approved use. It does not treat an ingredient name as proof of approval.
Oral peptides: do peptide pills work?
Most oral peptides break down when swallowed. See which FDA-approved peptide pills are built to work, what their studies measured, and how to check a peptide pill claim.